Analyst price target hikes fuel the rally. Chemours Company (CC) shares surged 9.41% to $19.30 on Tuesday, adding roughly $249 million in market capitalization. The specialty chemicals maker has climbed steadily following a series of bullish analyst revisions over the past three weeks, with three major firms raising their price targets by an average of 24%.
Wall Street turns more optimistic. UBS reiterated its Buy rating on February 23 and lifted its price target to $23 from $18, implying 19% upside from current levels. Goldman Sachs followed on February 25, maintaining Neutral but raising its target to $18 from $14. Most recently, Mizuho reaffirmed Outperform on March 5 and boosted its target to $21 from $17. The upgrades suggest improving sentiment around Chemours’ titanium dioxide and thermal management solutions businesses.
Volume confirms conviction. Trading volume reached 4.14 million shares, running 26% above the 3.28 million average. The elevated activity indicates institutional participation rather than retail-driven momentum, lending credibility to the move. Chemours’ $2.90 billion market cap positions it as a mid-cap play in the Basic Materials sector.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.